Clinical Trials | January 12, 2026
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Vanda strongly disputes the FDA’s reasoning
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Subscribe To Our Newsletter & Stay Updated
